(Bloomberg) -- Novavax ... vaccine at its own cost. Shares of Sanofi rose slightly in early trading in Paris. The stock was down about 5% in the past 12 months through Thursday’s close. The deal ...
Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The top-three investor in Novavax ... malaria vaccine – which uses its Matrix-M adjuvant – had been shipped by partner Serum Institute of India to Africa. The deal with Sanofi includes ...
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry. Novavax stock ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...